The Patient-Centered Outcomes Research Institute is offering up to $90 million in support for studies that address practical comparative questions faced by patients, clinicians and other healthcare ...
High prices for cancer drugs preclude independent comparative effectiveness trials that would seek to establish equally effective but cheaper alternatives — thereby protecting the market share of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results